Actively Recruiting
Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia
Led by Chinese PLA General Hospital · Updated on 2026-04-07
120
Participants Needed
1
Research Sites
162 weeks
Total Duration
On this page
Sponsors
C
Chinese PLA General Hospital
Lead Sponsor
9
940 Hospital of the People's Liberation Army Joint Logistic Support Force
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study is a multicenter, prospective, randomized, controlled clinical trial, observing the efficacy and safety of the CACAG+Venetoclax regimen (Chidamide + Azacitidine + Aclarubicin + Cytarabine + Recombinant Human Granulocyte Colony-Stimulating Factor + Venetoclax) in elderly patients with newly diagnosed Acute Myeloid Leukemia (AML). The control group applies the standard "3+7" regimen. The aim is to improve the remission rate of AML patients, reduce the probability of adverse events, and thereby improve patient prognosis and extend patient survival.
CONDITIONS
Official Title
Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Voluntarily agree to participate and sign informed consent
- Age between 60 and 75 years
- Newly diagnosed with Acute Myeloid Leukemia according to 2021 Chinese Medical Association standards
- No severe allergy history
- Liver function with ALT and AST ≤ 2.5 times upper normal limit and bilirubin ≤ 2 times upper normal limit
- Normal renal function with creatinine ≤ upper normal limit
- No uncontrollable infections or severe mental illnesses
- Performance status score 0-3 (ECOG) and expected survival of at least 4 months
You will not qualify if you...
- Allergy or contraindication to study medications
- Pregnant or breastfeeding women
- Active infections
- Long-term smoking or alcohol abuse affecting trial evaluation
- Mental disorders or inability to cooperate with treatment and examinations
- Major organ surgery within last 6 weeks
- Abnormal liver function with bilirubin > 1.5 times upper normal limit or ALT/AST > 2.5 times upper normal limit, or liver infiltration with ALT/AST > 5 times upper normal limit
- Abnormal renal function with creatinine > 1.5 times upper normal limit
- Investigator judgment of unsuitability (e.g., poor compliance, drug abuse)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Chinese PLA General Hospital
Beijing, None Selected, China, 100853
Actively Recruiting
Research Team
D
Dahong Liu Liu, doctor
CONTACT
L
Liping Dou, Doctor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here